REDWOOD CITY Calif.,
Nov. 23, 2011 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain, today announced that Richard
King, President and Chief Executive Officer, will present at
the 23rd Annual Piper Jaffray Health Care Conference in
New York City at the New York
Palace Hotel. The presentation is scheduled for Tuesday, November 29 at 9:30 a.m. ET.
The presentation will be webcast live and can be accessed
through:
http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=ACRX&item_id=4228786.
For those who are not available to listen to the live broadcast,
the presentation will be archived and available through
http://www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
Based in Redwood City, CA,
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) is a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for the treatment of
acute and breakthrough pain. AcelRx's lead product candidate, the
ARX-01 Sufentanil NanoTab PCA System, which is in preparation for
Phase 3 clinical development, is designed to solve the problems
associated with post-operative intravenous patient-controlled
analgesia which has been shown to cause harm to patients following
surgery because of the side effects of morphine, the invasive IV
route of delivery and the inherent potential for programming and
delivery errors associated with the complexity of infusion pumps.
AcelRx has two additional product candidates which have completed
Phase 2 clinical development: ARX-02 for the treatment of cancer
breakthrough pain, and ARX-03 for providing mild sedation, anxiety
reduction and pain relief for patients undergoing painful
procedures in a physician's office. A fourth product candidate,
ARX-04, is a sufentanil product for the treatment of
moderate-to-severe acute pain that is expected to enter Phase 2
clinical development in the fourth quarter of 2011 under a grant
from the US Army Medical Research and Material Command.
SOURCE AcelRx Pharmaceuticals, Inc.